Skip to main content
Erschienen in: Journal of Cardiovascular Translational Research 1/2008

01.03.2008

Approaching Biomarker Discovery through Genomics

verfasst von: Stephen S. Rich

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

The promise of genomic medicine lies in the ability to identify those factors that modify risk of disease at the individual level and, once identified, to be able to provide a personalized treatment or intervention to ablate the disease process. This concept is based upon a number of assumptions and current limitations that genomic science has yet to address. Critical to the development of personalized medicine is the determination of the genetic and epidemiologic cause of complex human disease, such as coronary heart disease, diabetes, asthma, and stroke. The risk factors that predispose an individual to any one of these disorders may not be unique, and the genomic profiles may be similar. Increasing the complexity of understanding the pathogenesis of these disorders is the growing recognition that the genetic risk factors likely interact not only with each other but also with poorly understood environmental factors. Ultimately, the prediction of an individual’s risk for any disorder will be determined by their genotype and their environmental exposures; however, in the absence of a defined genomic fingerprint, a subset of confirmed genetic risk factors can be used to help define biomarkers of disease. Clinically validated biomarkers can then serve as surrogates for the combined effects of genotype and environment and provide insights into disease pathogenesis.
Literatur
1.
Zurück zum Zitat Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S. (2003) A vision for the future of genomics research. A blueprint for the genomic era. Nature, 422, 835–847.PubMedCrossRef Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S. (2003) A vision for the future of genomics research. A blueprint for the genomic era. Nature, 422, 835–847.PubMedCrossRef
2.
Zurück zum Zitat The International HapMap Consortium. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851–862.CrossRef The International HapMap Consortium. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851–862.CrossRef
3.
Zurück zum Zitat Evans, D. M., Cardon, L. R. (2004) Guidelines for genotyping in genomewide linkage studies: Single-Nucleotide-Polymorphism maps versus microsatellite maps. American Journal of Human Genetics, 75, 687–692.PubMedCrossRef Evans, D. M., Cardon, L. R. (2004) Guidelines for genotyping in genomewide linkage studies: Single-Nucleotide-Polymorphism maps versus microsatellite maps. American Journal of Human Genetics, 75, 687–692.PubMedCrossRef
4.
Zurück zum Zitat Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., et al. (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genetics, 36, 233–239.PubMedCrossRef Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., et al. (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genetics, 36, 233–239.PubMedCrossRef
5.
Zurück zum Zitat Hakonarson, H., Thorvaldsson, S., Helgadottir, A., Gudbjartsson, D., Zink, F., Andresdotttir, M. et al. (2005) Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. Journal of the American Medical Association, 293, 2245–2256.PubMedCrossRef Hakonarson, H., Thorvaldsson, S., Helgadottir, A., Gudbjartsson, D., Zink, F., Andresdotttir, M. et al. (2005) Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. Journal of the American Medical Association, 293, 2245–2256.PubMedCrossRef
6.
Zurück zum Zitat Meschia, J. F., Brott, T. G., Brown, R. D., Crook, R., Worrall, B. B., Kissela, B., et al. (2005) Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Annals of Neurology, 58, 351–361.PubMedCrossRef Meschia, J. F., Brott, T. G., Brown, R. D., Crook, R., Worrall, B. B., Kissela, B., et al. (2005) Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Annals of Neurology, 58, 351–361.PubMedCrossRef
7.
Zurück zum Zitat Zee, R. Y. L., Cheng, S., Hegener, H. H., Erlich, H. A., Ridker, P. M. (2006) Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke. A nested case-control approach. Stroke, 37, 2007–2011.PubMedCrossRef Zee, R. Y. L., Cheng, S., Hegener, H. H., Erlich, H. A., Ridker, P. M. (2006) Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke. A nested case-control approach. Stroke, 37, 2007–2011.PubMedCrossRef
8.
Zurück zum Zitat Maznyczka, A., Mangino, M., Whittaker, A., Braund, P., Palmer, T., Tobin, M., (2007) Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction. Clinical Science, 112, 411–416.PubMedCrossRef Maznyczka, A., Mangino, M., Whittaker, A., Braund, P., Palmer, T., Tobin, M., (2007) Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction. Clinical Science, 112, 411–416.PubMedCrossRef
9.
Zurück zum Zitat Wilson, P. W., D’Agostino, R. B., Levy, D., Berlanger, A. M., Silbershatz, H., Kannel, W. B. (1998) Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837–1847.PubMed Wilson, P. W., D’Agostino, R. B., Levy, D., Berlanger, A. M., Silbershatz, H., Kannel, W. B. (1998) Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837–1847.PubMed
10.
Zurück zum Zitat Greenland, P., Knoll, M. D., Stamler, J., Neaton, J. D., Dyer, A. R., Garside, D. B., et al. (2001) Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. Journal of the American Medical Association, 290, 891–897.CrossRef Greenland, P., Knoll, M. D., Stamler, J., Neaton, J. D., Dyer, A. R., Garside, D. B., et al. (2001) Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. Journal of the American Medical Association, 290, 891–897.CrossRef
11.
Zurück zum Zitat Ridker, P. M., Riffai, N., Rose, L., Buring, J. E., Cook, N. R. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine, 347, 1557–1565.PubMedCrossRef Ridker, P. M., Riffai, N., Rose, L., Buring, J. E., Cook, N. R. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine, 347, 1557–1565.PubMedCrossRef
12.
Zurück zum Zitat Wang, T. J., Gona, P., Larson, M. G., Tofler, G. H., Levy, D., Newton-Cheh, C., et al. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. New England Journal of Medicine, 355, 2631–2639.PubMedCrossRef Wang, T. J., Gona, P., Larson, M. G., Tofler, G. H., Levy, D., Newton-Cheh, C., et al. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. New England Journal of Medicine, 355, 2631–2639.PubMedCrossRef
13.
Zurück zum Zitat Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447, 661–678.CrossRef Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447, 661–678.CrossRef
14.
Zurück zum Zitat The GAIN Collaborative Research Group. (2007) New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nature Genetics, 39, 1045–1051.CrossRef The GAIN Collaborative Research Group. (2007) New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nature Genetics, 39, 1045–1051.CrossRef
15.
Zurück zum Zitat Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A. et al. (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science, 316, 1491–1493.PubMedCrossRef Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A. et al. (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science, 316, 1491–1493.PubMedCrossRef
16.
Zurück zum Zitat Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., et al. (2007) Genomewide association analysis of coronary artery disease. New England Journal of Medicine, 357, 443–453.PubMedCrossRef Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., et al. (2007) Genomewide association analysis of coronary artery disease. New England Journal of Medicine, 357, 443–453.PubMedCrossRef
17.
Zurück zum Zitat Dixon, A. L., Liang, L., Moffatt, M. F., Chen, W., Heath, S., Wong, K. C. C., et al. (2007) A genome-wide association study of global gene expression. Nature Genetics, 39, 1202–1207.PubMedCrossRef Dixon, A. L., Liang, L., Moffatt, M. F., Chen, W., Heath, S., Wong, K. C. C., et al. (2007) A genome-wide association study of global gene expression. Nature Genetics, 39, 1202–1207.PubMedCrossRef
18.
Zurück zum Zitat Goring, H. H. H., Curran, J. E., Johnson, M. P., Dyer, T. D., Charlesworth, J., Cole, S. A., et al. (2007) Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nature Genetics, 39, 1208–1216.PubMedCrossRef Goring, H. H. H., Curran, J. E., Johnson, M. P., Dyer, T. D., Charlesworth, J., Cole, S. A., et al. (2007) Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nature Genetics, 39, 1208–1216.PubMedCrossRef
19.
Zurück zum Zitat Stranger, B. E., Nica, A. C., Forrest, M. S., Dimas, A., Bird, C. P., Beazley, C., et al. (2007) Population genetics of human gene expression. Nature Genetics, 39, 1217–1224.PubMedCrossRef Stranger, B. E., Nica, A. C., Forrest, M. S., Dimas, A., Bird, C. P., Beazley, C., et al. (2007) Population genetics of human gene expression. Nature Genetics, 39, 1217–1224.PubMedCrossRef
Metadaten
Titel
Approaching Biomarker Discovery through Genomics
verfasst von
Stephen S. Rich
Publikationsdatum
01.03.2008
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 1/2008
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-007-9003-z

Weitere Artikel der Ausgabe 1/2008

Journal of Cardiovascular Translational Research 1/2008 Zur Ausgabe

Innovation, Translation, Education

A GINA Primer

EditorialNotes

GINA Update

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.